Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Oct 14, 2014; 20(38): 13741-13755
Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.13741
Table 7 Clinical trials of cetuximab and panitumumab
PatientsPhaseTreatmentnOS (m)PFS (m)RRDCR
Previously untreated advanced gastric cancer (EXPAND)IIICapecitabine + cisplatin44910.75.629%71%
Capecitabine + cisplatin + cetuximab4559.44.430%73%
Untreated metastatic or locally advanced oesophagogastric adenocarcinoma (REAL 3)IIIEOC (epirubicin + oxaliplatin + capecitabine)27511.36.042%63%
Modified dose EOC + panitumumab2788.87.446%64%